Production|HQD Launches APEX With 1.47" HD Screen and 5-45W Output

Apr.28.2025
Production|HQD Launches APEX With 1.47" HD Screen and 5-45W Output
HQD recently launched the open e-cigarette APEX, equipped with a 1.47-inch HD touchscreen with 5-45W wide-range power output, supporting three kinds of interchangeable cartridges of 0.4Ω, 0.8Ω and 1.2Ω, and adapted to MTL to DTL modes. The product has been launched on the brand's official website and social media, but has not yet landed on overseas distributor platforms.

Special Statement:

1.This article is intended for internal industry communication only and does not make any recommendations for specific brands or products.

2.This article is prohibited for minors to access.

3.The images presented in this article are used solely to depict facts and are not intended as advertisements for any products.


Product highlights:

 

·The 1.47 inch HD touchscreen interaction: HQD APEX can display real-time battery power, wattage, and work status. 

·Wide range power output of 5-45W: HQD APEX is compatible with 0.4Ω, 0.8Ω, 1.2Ω three-level replaceable pods, supporting MTL (mouth to lung) to DTL (direct to lung) mode switching. 

·Wide range power output: Compared to similar products (such as VOZOL ACE PRO, Geekvape Soul 2 Pod Kit), HQD APEX has the widest power range (5W-45W). 

 

It is worth noting that e-cigarette brand HQD has launched a new open system - APEX on its official website, featuring a 1.47 inch HD touchscreen and supporting 5-45W wide range power output. At present, it has not yet been listed on e-cigarette distributor websites.

 

Equipped with a 1,000mAh battery for wide-range power output of 5-45W

 

2Firsts collected the parameter information of HQD APEX, as shown in the table below:

 

Production|HQD Launches APEX With 1.47
HQD APEX Parameter Information | Mapping: 2Firsts

 

Prior to this, the e-cigarette brand VAPORESSO had also released an open system named "APEX" - the Vaporesso Apex Pod Kit. It is reported that a tactical competitive game called "Apex Legends" launched in 2019 also uses this name.

 

Production|HQD Launches APEX With 1.47
Vaporesso Apex | Image source: Vaporesso

 

From a product specification point of view, the HQD APEX is equipped with a 1,000mAh battery, which is lower compared to similar products such as the VOZOL ACE PRO (1400mAh) and Vaporesso Apex Pod Kit (2000mAh).

 

In addition, the HQD APEX is equipped with three different resistance replaceable pods of 0.4Ω, 0.8Ω, and 1.2Ω, corresponding to an output power range of 5W to 45W. Compared to several other brands such as VOZOL, Geekvape, FRESOR, the HQD APEX has a wider power output range, supporting the switch from MTL (mouth-to-lung) to DTL (direct-to-lung) modes.

 

Production|HQD Launches APEX With 1.47
HQD APEX product information | Image source: HQD

 

It is worth noting that, while the HQD APEX product page displays three different resistance values of replaceable pods (0.4Ω, 0.8Ω, 1.2Ω), the official website states that the product is currently available in 0.8Ω and 1.2Ω variants. However, HQD APEX plans to release a version compatible with 0.4Ω pods in the future.

 

Production|HQD Launches APEX With 1.47
HQD APEX Product Information | Image Source: HQD

 

Equipped with a 1.47-inch HD touchscreen

 

Like many other multi-brand cartridge-style, open-system products that have been introduced before, the HQD APEX is equipped with a 1.47-inch HD touchscreen that can display real-time information such as battery life, power output, and operational status, and supports animated feedback. The product also features airflow adjustment on the side, and includes a side button that provides access to all functions.

 

Production|HQD Launches APEX With 1.47
HQD APEX Product Information | Image Source: HQD

 

Previously, the VOZOL brand launched a pod system e-cigarette product called the VOZOL Ace Max, which also features a 1.47-inch touchscreen display showing data such as power, puff count, and battery level.

 

 

Production|HQD Launches APEX With 1.47
VOZOL Ace Max | Image source: VOZOL

 

Online sales have not been conducted yet

 

Currently, HQD APEX has been launched on the HQD brand official website and is being promoted simultaneously on the brand's Facebook and Instagram official accounts. The HQD brand has now released a variety of open-system products including HQD ZEST, HQD CIRAK, and HQD EOS 2.0.

 

Production|HQD Launches APEX With 1.47
HQD APEX promotional information | Image source: Instagram

 

HQD APEX is currently not available for sale on overseas e-cigarette distributor websites; a search on the UK Medicines and Healthcare products Regulatory Agency (MHRA) e-cigarette product announcement database did not yield any information on HQD APEX, suggesting the product may not be targeted towards the UK market.

 


 

2FIRSTS focuses on providing readers with the latest information on new products in the tobacco industry. We welcome contributions from readers to help us gather and share firsthand information in the e-cigarette field.

 

If you have any unique insights or information, please feel free to contact us anytime via email at info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22